The occurrence of benign brain tumours in transgender individuals during cross-sex hormone treatment

@article{Nota2018TheOO,
  title={The occurrence of benign brain tumours in transgender individuals during cross-sex hormone treatment},
  author={Nienke M Nota and Chantal Maria Wiepjes and Christel JM. de Blok and Louis J. G. Gooren and Saskia M. Peerdeman and Baudewijntje P. C. Kreukels and Martin den Heijer},
  journal={Brain},
  year={2018},
  volume={141},
  pages={2047–2054}
}
Benign brain tumours may be hormone sensitive. [] Key Method This study was performed at the VU University Medical Centre in the Netherlands and consisted of 2555 transwomen (median age at start of cross-sex hormone treatment: 31 years, interquartile range 23-41) and 1373 transmen (median age 23 years, interquartile range 18-31) who were followed for 23 935 and 11 212 person-years, respectively. For each separate brain tumour, standardized incidence ratios with 95% confidence intervals were calculated. In…

Tables from this paper

Pituitary Adenomas in Transgender Individuals?

Pathologists may wish to be aware of the occurrence of pituitary adenomas in transgender individuals, although the incidence is quite low.

Management of endocrine disease: Optimal feminizing hormone treatment in transgender people.

Evidence is discussed regarding established and upcoming feminizing treatment for adult transgender women or for gender non-binary people seeking feminization, with special focus on the pharmacotherapy of feminizing hormonal therapy.

Sex-specific aspects of epidemiology, molecular genetics and outcome: primary brain tumours

Exploring sex-specific aspects of neuro-oncology should be studied more systematically and in more depth in order to uncover the biological reasons for known sex differences in this disease.

Gender-affirming hormone therapy associated with multiple meningiomas and atypical histology in a transgender woman

An association between high-dose CPA and estradiol and the development, growth and regression of meningiomas in a transgender woman is demonstrated.

Hyperprolactinemia and association with prolactinoma in transwomen receiving gender affirming hormone treatment

As the number of transwomen seeking GAHT continues to increase, hyperprolactinemia and GAHT-associated prolactinoma may become an increasingly important component of endocrine practice.

Cancer Risk in Transgender People.

Reproductive Endocrinology Reference Intervals for Transgender Women on Stable Hormone Therapy.

Reference intervals specific to transgender women should be applied when evaluating reproductive endocrine analytes related to reproductive endocrinology in a cohort of healthy gender nonconforming individuals on stable feminizing hormone therapy.

References

SHOWING 1-10 OF 46 REFERENCES

Meningiomas in three male‐to‐female transgender subjects using oestrogens/progestogens and review of the literature

The role of female sex hormones in the development and growth of meningiomas is supported and the decision to stop or continue cross‐sex hormone therapy in these particular patients should be carefully reconsidered individually.

Diagnosis of prolactinoma in two male‐to‐female transsexual subjects following high‐dose cross‐sex hormone therapy

Two new cases of prolactinomas are reported in male‐to‐female transsexual persons, one in a 41‐year‐old subject who had used nonsupervised high‐dose oestrogen treatment since the age of 23 years and another one inA 42 year old who had initiated oestrogens treatment at the ageOf 17 years, both cases responded well to treatment with cabergoline treatment whereupon serum Prolactin normalised.

A European Network for the Investigation of Gender Incongruence: Endocrine Part.

The Amsterdam Cohort of Gender Dysphoria Study (1972-2015): Trends in Prevalence, Treatment, and Regrets.

Prolactin-producing pituitary adenoma in a male-to-female transsexual patient with protracted estrogen administration. A morphologic study.

The present case, which is the first to describe structural findings of a pituitary adenoma in a transsexual patient who was given estrogen, reinforces the view that protracted stimulation may play a role in the genesis of endocrine tumors.

Presentation of a meningioma in a transwoman after nine years of cyproterone acetate and estradiol intake: case report and literature review

This report highlights the importance to record all the cases of meningiomas in high dose CPA-users, in order to improve data, and may suggest use of alternative treatment for transwomen.

Autonomous prolactin secretion in two male-to-female transgender patients using conventional oestrogen dosages

It is suggested that in MTF patients an excessive first year increase in serum Prolactin concentration may identify patients at risk for autonomous prolactin secretion later in life.

Hormonal therapies and meningioma: is there a link?

Transient Elevated Serum Prolactin in Trans Women Is Caused by Cyproterone Acetate Treatment.

CPA is likely to cause a temporary increase in serum Prolactin, with prolactin levels returning to normal after orchiectomy and CPA discontinuation, according to a retrospective analysis of trans women receiving gender affirming hormones.